Other Viruses Citation List: December 21 - January 3, 2013
HCMV
1. C-3 Halo and 3-Methyl Substituted 5'-nor-3-deazaaristeromycins: Synthesis and Antiviral Properties. Liu, C., Q. Chen, M. Yang, and S.W. Schneller. Bioorganic & Medicinal Chemistry, 2013. 21(1): p. 359-64; PMID[23176752].
[PubMed] OV_1221-010312.
Hepatitis C Virus
2. The Anti-viral Effect of Sorafenib in Hepatitis C-related Hepatocellular Carcinoma. Cabrera, R., A.R. Limaye, P. Horne, R. Mills, C. Soldevila-Pico, V. Clark, G. Morelli, R. Firpi, and D.R. Nelson. Alimentary Pharmacology & Therapeutics, 2013. 37(1): p. 91-7; PMID[23094860].
[PubMed] OV_1221-010312.
3. Thumb Inhibitor Binding Eliminates Functionally Important Dynamics in the Hepatitis C Virus RNA Polymerase. Davis, B.C. and I.F. Thorpe. Proteins, 2013. 81(1): p. 40-52; PMID[22855387].
[PubMed] OV_1221-010312.
4. Boceprevir with Peginterferon alfa-2A-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Flamm, S.L., E. Lawitz, I. Jacobson, M. Bourliere, C. Hezode, J.M. Vierling, B.R. Bacon, C. Niederau, M. Sherman, V. Goteti, H.L. Sings, R.O. Barnard, J.A. Howe, L.D. Pedicone, M.H. Burroughs, C.A. Brass, J.K. Albrecht, and F. Poordad. Clinical Gastroenterology and Hepatology, 2013. 11(1): p. 81-87 e4; PMID[23064222].
[PubMed] OV_1221-010312.
5. Combinations of Interferon Lambda with Direct-acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication. Friborg, J., S. Levine, C. Chen, A.K. Sheaffer, S. Chaniewski, and F. McPhee. Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[23274666].
[PubMed] OV_1221-010312.
6. Combination Treatment with HCV Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1A, 2A and 3A Virus. Gottwein, J.M., S.B. Jensen, Y.P. Li, L. Ghanem, T.K. Scheel, S.B. Serre, L. Mikkelsen, and J. Bukh. Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[23274664].
[PubMed] OV_1221-010312.
7. Inhibition of the Interaction between NS3 Protease and HCV IRES with a Small Peptide: A Novel Therapeutic Strategy. Ray, U., C.L. Roy, A. Kumar, P. Mani, A.P. Joseph, G. Sudha, D.P. Sarkar, N. Srinivasan, and S. Das. Molecular Therapy : the Journal of the American Society of Gene Therapy, 2013. 21(1): p. 57-67; PMID[22910295].
[PubMed] OV_1221-010312.
HSV-1
8. Synergistic Activity of Amenamevir (ASP2151) with Nucleoside Analogs against Herpes Simplex Virus Types 1 and 2 and Varicella-Zoster Virus. Chono, K., K. Katsumata, H. Suzuki, and K. Shiraki. Antiviral Research, 2012. [Epub ahead of print]; PMID[23261844].
[PubMed] OV_1221-010312.
Citations from the ISI Web of Knowledge Listings for O.V.
9. Neutralization Activity and Kinetics of Two Broad-Range Human Monoclonal IGG1 Derived from Recombinant FAB Fragments and Directed against Hepatitis C Virus E2 Glycoprotein. Diotti, R.A., G.A. Sautto, L. Solforosi, N. Mancini, M. Clementi, and R. Burioni. New Microbiologica, 2012. 35(4): p. 475-479; ISI[000311469500012].
[WOS] OV_1221-010312.
10. A Cell Permeable Hairpin Peptide Inhibits Hepatitis C Viral NS5A-Mediated Translation and Virus Production. Khachatoorian, R., V. Arumugaswami, P. Ruchala, E.M. Maloney, S. Raychaudhuri, E. Miao, A. Dasgupta, and S.W. French. Faseb Journal, 2012. 26; ISI[000310711301807].
[WOS] OV_1221-010312.
11. Strong Antiviral Activity of the New L-Hydroxycytidine Derivative, L-HYD4FC, in HBV-Infected Human Chimeric UPA/SCID Mice. Volz, T., M. Lutgehetmann, L. Allweiss, M. Warlich, J. Bierwolf, J.M. Pollok, J. Petersen, E. Matthes, and M. Dandri. Antiviral Therapy, 2012. 17(4): p. 623-631; ISI[000311027200004].
[WOS] OV_1221-010312.
12. Antiviral Activity of FNC, 2 '-Deoxy-2 '-β-fluoro-4 '-azidocytidine, against Human and Duck HBV Replication. Zheng, L.Y., Q. Wang, X.R. Yang, X.H. Guo, L. Chen, L. Tao, L.H. Dong, Y.J. Li, H.Y. An, X.J. Yu, Q.D. Wang, and J.B. Chang. Antiviral Therapy, 2012. 17(4): p. 679-687; ISI[000311027200009].
[WOS] OV_1221-010312.